Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Miglustat oral solution safety and efficacy study in pediatric patients with CLN3 disease

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

CLN3 Disease is a rare inherited condition that begins in childhood and leads to progressive loss of vision, difficulties with movement, seizures, and changes in behavior and thinking. The study will use a medicine called Miglustat that is supplied as a flavored oral liquid (Batten‑1) taken by mouth each day.

The aim of the study is to find out whether daily treatment with this medicine can slow the worsening of the disease’s signs and symptoms during a one‑year period. Participants will receive the study drug for 52 weeks and will attend regular visits where simple tests will be done to check eyesight (using a chart that measures how clearly letters can be seen), walking ability, speech clarity, and overall health. Small blood samples will also be taken to look for substances that may indicate disease activity. The study does not involve any comparison with another treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Start Treatment

    You will receive Batten-1, an oral liquid formulation containing the active substance miglustat.

    The prescribed dose is 600 mg taken by mouth each day.

    The medication will be taken for a total of 52 weeks.

  2. Step 2

    Baseline Assessments

    Before the first dose, a series of tests will be performed to record your starting condition.

    Your visual acuity will be measured with the ETDRS LogMAR chart, or an adapted test for children under 6 years, such as LEA symbols.

    You will complete the Unified Batten Disease Rating Scale (UBDRS) Clinical Global Impression, Capability subscale, and Physical Assessment subscale (including gait and speech clarity).

    A motor function item from the modified Hamburg Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) scale will be recorded.

    Blood samples will be taken to measure serum biomarkers, including neurofilament light chains and glycosphingolipids.

  3. Step 3

    Ongoing Monitoring

    During the 52‑week treatment period, you will attend regular clinic visits to check safety and how well the medication is being tolerated.

    At each visit, the study team will ask about any side effects and verify that the daily dose is being taken as prescribed.

    Periodic repeats of the visual acuity test and the UBDRS assessments may be performed to track changes over time.

  4. Step 4

    Week 52 Evaluation

    At the end of the 52‑week period, all baseline assessments will be repeated.

    Your visual acuity will be measured again with the same method used at baseline.

    The UBDRS Clinical Global Impression, Capability subscale, Physical Assessment subscale, and motor function item will be reassessed.

    Blood will be drawn again to evaluate changes in serum biomarkers such as neurofilament light chains and glycosphingolipids.

    These results will be compared with the baseline values to determine the effect of Batten-1 on disease progression.

  5. Step 5

    Study Completion

    After the final assessments, the study will be concluded for you.

    All data collected during the trial will be used to evaluate the efficacy and safety of the treatment.

Who can join the trial?

6 criteria

  • Be a boy or girl between 4 and 17 years old and have a vision test result called best corrected visual acuity that is 1.9 LogMAR (about “counting fingers”) or worse in at least one eye at the start of the study. Best corrected visual acuity means the sharpest vision possible after using glasses or contact lenses, and LogMAR is a scale doctors use to measure how well you can see; a higher number means poorer vision.
  • Have a parent or legal guardian sign a written informed consent form allowing you to join the study. If you are older than 7 years, you can also sign a simpler form called an assent or give a verbal agreement if you cannot see well enough to sign.
  • Have a confirmed genetic diagnosis of CLN3 disease. This means lab testing shows either:
    • Two genetic changes called pathogenic (disease‑causing) variants in the CLN3 gene, or
    • One confirmed disease‑causing variant plus one “variant of unknown significance” (a change whose effect is not yet known), together with either special cell findings seen under a microscope (electron microscopy) or a blood test showing vacuolated lymphocytes (white blood cells that look empty).
    • If you are capable of becoming pregnant and are sexually active, you must use a very reliable form of contraception (birth control) that has a Pearl‑Index lower than 1 % (meaning fewer than 1 pregnancy per 100 women per year). You must keep using it for the whole study and for 30 days after the last dose.
    • Be able to complete all study visits and tests, such as having no cataracts (clouding of the eye’s lens) that would stop the vision test, and be able to come back to the clinic when scheduled, with help from a caregiver if needed.

Who cannot join the trial?

14 criteria

  • People who have a genetic change that only causes eye problems (non‑syndromic variants with a vision‑only phenotype), or who are older than 8 years and show only eye problems at the start of the study, cannot join.
  • Anyone who took the medicine miglustat within one week before the first study visit, or who plans to receive any other experimental device or drug during the study, is not eligible.
  • People with a health problem that the doctor thinks could affect the study results or increase the chance of side effects (adverse events), including any active cancer (malignancy) except skin cancers that are not melanoma, cannot participate.
  • If the doctor finds a serious abnormal result in the blood or chemistry tests (called clinical laboratory values, such as blood counts or chemical levels) during screening, the person cannot join.
  • Individuals with serious heart problems (cardiac impairment) such as abnormal heart rhythm patterns (prolonged QTc), thickened heart muscle walls (ventricular hypertrophy), problems with the heart’s natural pacemaker (sinus node dysfunction) that cause very slow heart rates (severe bradycardia), or other electrical conduction issues are excluded.
  • People who are living in a facility because a court or government order requires it are not allowed to take part.
  • Anyone who is allergic or overly sensitive (hypersensitivity) to miglustat or any ingredient of the study medication (Investigational Medicinal Product, IMP) must be excluded.
  • People with severe kidney disease, measured by an estimated kidney function called Glomerular Filtration Rate (eGFR) that is less than 30 mL/min, cannot join.
  • Those who have a history of HIV infection, hepatitis B, hepatitis C, or who test positive for any of these infections at screening are not eligible.
  • Individuals who might feel pressured to join because they expect special benefits or fear retaliation, or who are immediate family members of staff working on the study, are excluded.
  • Anyone whose best corrected vision test score (called LogMAR) is higher than 1.9, indicating very poor vision, cannot participate.
  • People with eye conditions that could affect vision testing, such as cataract, glaucoma, diabetes‑related eye disease, or amblyopia (lazy eye), are not eligible.
  • Those who have already received gene therapy or stem cell therapy aimed at changing the course of CLN3 disease are excluded.
  • Anyone who took part in another experimental treatment study within the three months before screening cannot join.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Batten-1 is an oral liquid medication that contains the active ingredient miglustat. In this study, children with CLN3 disease take Batten-1 by mouth once daily. The medicine is designed to help slow the buildup of certain substances inside cells that cause damage in this rare disorder. By reducing this buildup, Batten-1 aims to slow the worsening of symptoms and improve the overall health and daily functioning of the participants over the one‑year treatment period.

What is already known about the treatment

Miglustat - This medication is given as an oral liquid solution that is swallowed, with a typical dose of 600 mg taken each day. Miglustat is an approved orphan drug that is already used for some rare storage diseases and is described in medical literature, and it is now being tested for CLN3 disease in children. It is mainly used to treat conditions where harmful fats build up in cells, and it works by blocking an enzyme that makes those fats, helping to reduce their accumulation. Pharmacologically, it is classified as an iminosugar that inhibits glucosylceramide synthase.

Investigated diseases

Juvenile neuronal ceroid lipofuscinosis (CLN3 disease) - Juvenile neuronal ceroid lipofuscinosis (CLN3 disease) is a rare inherited disorder that leads to the buildup of fatty substances in the brain and retina. It usually starts in early childhood with loss of vision caused by retinal degeneration. As the disease progresses, children experience seizures, decline in cognitive abilities, and changes in behavior. Motor function gradually worsens, making walking and speech increasingly difficult. Over the years the range of symptoms expands and becomes more severe.
Trial detailsLast updated 18 Nov 2026
Age0-17PhasePhase IIITrial ID2023-510533-29-00Protocol codeBatten-1-02Estimated enrolment26 patientsSponsorTheranexus

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.